Cell line · CVCL_4784
Papers60
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 60
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The establishment of prostate-specific, SKP2 humanized mice by CRISPR knock-in method reveals neoplastic initiation and microenvironmental reprogramming. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with BCL-XL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | J Clin Invest | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The YAP1-NPM1 nuclear complex regulates MYC and reveals a targetable oncogenic node. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibiting stearoyl-CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response. | FEBS Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell maintenance and immune evasion in enzalutamide-resistant prostate cancer. | Theranostics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CAMK1D activates AMPK/PINK1/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Effect of TGF-β mediated phenotypic changes on prostate cancer cell anoikis response. | Oncogene | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer. | PLoS One | 2025 | Its Methods give the RRID and name the line | PubMed | |
| tRF-21LeuTAA Promotes Oxidative Stress by Altering Glutathione Metabolic Enzymes to Support Prostate Cancer Progression. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CAF-mediated regulation of prostate cancer stem cell stemness via the Wnt/β-catenin and SDF-1/CXCR4 pathways in castration-resistant prostate cancer. | Front Cell Dev Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Discovery and Biosynthesis of Nyuzenamides D and E by Genome Mining in Streptomyces hygroscopicus. | ACS Omega | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ezetimibe Engineered L14-8 Suppresses Advanced Prostate Cancer by Activating PLK1/TP53-SAT1-Induced Ferroptosis. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_4784/papers